Medtronic announced a 13.7% increase in revenue to $9.8 billion for Q1 of fiscal year 2027, driven by strong growth across cardiovascular, neuroscience, and medical surgical segments. The company raised its full-year organic revenue growth guidance to 7.25%-7.75% and non-GAAP EPS guidance to $5.94-$6.00, reflecting confidence in its innovation pipeline and recent acquisitions. Key growth areas include cardiac rhythm management, cardiac ablation solutions, and pelvic health, supported by new product approvals and strategic investments. This strong start positions Medtronic for sustained long-term growth and expanded patient impact.
Medtronic has made a strategic investment of up to $80 million in Pi-Cardia, a company specializing in leaflet modification technologies for structural heart disease. This investment supports Medtronic's goal to enhance its structural heart portfolio...
Despite two major recessions in the past two decades, four healthcare companies—Johnson & Johnson, Abbott Laboratories, Medtronic, and Becton Dickinson—consistently raised their dividends each quarter. Their strong cash flows and inelastic demand for...
The August jobs report is crucial for the Federal Reserve's decision on a potential September rate hike, with strong labor data increasing the odds. Broadcom faces downside risk ahead of earnings due to high AI expectations, while Apple transitions t...
